UBS Initiates Coverage of Inchcape (IHCPF) with Buy Recommendation

UBS initiated coverage on Inchcape (OTCPK:IHCPF) with a Buy recommendation on September 18, 2025, with analysts projecting an average one-year price target of $12.50/share, representing a 19.72% upside from its latest closing price of $10.44. The company has projected annual revenue of $8,834MM (a 0.27% decrease) and non-GAAP EPS of $0.77. Institutional sentiment is positive, with 133 funds reporting positions, reflecting a 2.31% increase in owners and a 3.53% rise in total institutional shares owned in the last quarter, with major holders like SMCWX and Fidelity Low-Priced Stock Fund significantly increasing their allocations.

Analysis

Inchcape (OTCPK:IHCPF) is exhibiting strong positive market sentiment, primarily driven by a new 'Buy' recommendation from UBS as of September 18, 2025. This initiation is supported by an average analyst price target of $12.50, which implies a significant 19.72% upside from its recent closing price of $10.44. However, this bullish analyst outlook is juxtaposed with the company's own modest fundamental projections, which include a slight annual revenue decrease of 0.27% to $8,834MM and a non-GAAP EPS of $0.77. Reinforcing the positive sentiment, institutional ownership trends are favorable, with a 2.31% increase in the number of funds holding the stock and a 3.53% rise in total shares owned over the last quarter. Notably, major holders like SMALLCAP WORLD FUND and Fidelity Low-Priced Stock Fund have increased their portfolio allocations by 17.09% and 22.28% respectively, signaling strong conviction. While some funds show minor share reductions, their overall portfolio allocation to IHCPF has still increased, suggesting the position's relative importance is growing even amidst minor rebalancing.

Key Decisions for Investors

• Investors should consider the new 'Buy' rating from UBS and the significant 19.72% price target upside as a primary bullish catalyst, reinforced by increasing institutional ownership and conviction from major funds.
• It is crucial to weigh the positive sentiment against the company's projected 0.27% revenue decline, as this fundamental headwind may challenge the realization of analyst price targets.
• Monitor upcoming earnings for any signs of revenue stabilization or growth that could validate the bullish thesis, and continue to track institutional fund flows for confirmation of sustained interest.